Medication info

Twin Beta-Al Tablet 40/5/5 mg (Telmisartan, Amlodipine, Rosuvastatin)

Prescription medicationApproval withdrawn
Ingredient · strength
Telmisartan›Strength being verifiedAmlodipine Besylate›Strength being verifiedRosuvastatin Calcium›Strength being verified
Manufacturer / importer
Daewoong Bio Co., Ltd.
Appearance
Pink oval film-coated tablet
Packaging
30 tablets (10 tablets x 3) / PTP
Approval status
Approval withdrawn

MFDS item code 201803887 · Approved 2018.10.02

This product's status changed to Approval withdrawn on 2023.04.25. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of hypertension, improvement of dyslipidemia, and inhibition of atherosclerosis progression and cardiovascular disease risk
Who uses it
Adults
Adult dosage
Take 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take it at the same time each day (e.g., in the morning). This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan/amlodipine combination and rosuvastatin. For patients taking a telmisartan/amlodipine combination and rosuvastatin as separate medicines, they may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. ○ Telmisartan/amlodipine combination Before starting the telmisartan/amlodipine combination, it is recommended to adjust the dose using the individual components (amlodipine or telmisartan). However, direct switching to the telmisartan/amlodipine combination may be considered when blood pressure is not controlled with the individual components, as follows: - 40/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or telmisartan 40 mg. - 80/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or this medicine 40/5 mg. - 40/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg. - 80/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg or this medicine 40/10 mg. ◦ Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. For patients with severe renal impairment, it is recommended to start treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. ◦ Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40 mg in patients with mild or moderate hepatic impairment. ◦ Older patients: In patients aged 75 years or older, amlodipine clearance is reduced; therefore, treatment should be started at a low dose and the dose increased gradually. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, regardless of meals. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, and most patients are controlled at this dose. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response; the dose may be increased to a maximum of 20 mg once daily. 2. Older patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering rosuvastatin 20 mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but exposure increased in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration in patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Ethnicity: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5 mg. A dose of 40 mg is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of rosuvastatin 40 mg is contraindicated in some of these patients. In a drug interaction study of the active ingredients in this medicine, telmisartan/amlodipine 80/10 mg and rosuvastatin 20 mg, in the presence of telmisartan/amlodipine, rosuvastatin Cmax increased approximately 2.4-fold and AUC approximately 1.3-fold. Therefore, when administering this medicine, assess the potential risk associated with the increase in rosuvastatin Cmax and monitor the patient closely.

Ingredients

Manufacturer
Daewoong Bio Co., Ltd.

Efficacy & effects

Treatment of hypertension, improvement of dyslipidemia, and inhibition of atherosclerosis progression and cardiovascular disease risk

  • Essential hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • combined hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol levels
  • smoking
  • family history of early coronary heart disease
View approved original text

This medication is used for patients with hypertension who do not have adequate blood pressure control with telmisartan and amlodipine combination therapy, while rosuvastatin acts as an adjunct to diet and exercise therapy for patients with hypercholesterolemia and hyperlipidemia. It also assists in treating familial hypercholesterolemia and dysbetalipoproteinemia, lowers total cholesterol and LDL cholesterol levels, and delays the progression of atherosclerosis. For patients over middle age at high risk for cardiovascular events, it is expected to reduce the risk of myocardial infarction, stroke, and arterial revascularization. Therefore, this medication is used to improve symptoms in patients requiring simultaneous management of blood pressure and lipids.

Dosage and Administration

Adult dosage

Take 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take it at the same time each day (e.g., in the morning). This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan/amlodipine combination and rosuvastatin. For patients taking a telmisartan/amlodipine combination and rosuvastatin as separate medicines, they may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. ○ Telmisartan/amlodipine combination Before starting the telmisartan/amlodipine combination, it is recommended to adjust the dose using the individual components (amlodipine or telmisartan). However, direct switching to the telmisartan/amlodipine combination may be considered when blood pressure is not controlled with the individual components, as follows: - 40/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or telmisartan 40 mg. - 80/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or this medicine 40/5 mg. - 40/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg. - 80/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg or this medicine 40/10 mg. ◦ Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. For patients with severe renal impairment, it is recommended to start treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. ◦ Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40 mg in patients with mild or moderate hepatic impairment. ◦ Older patients: In patients aged 75 years or older, amlodipine clearance is reduced; therefore, treatment should be started at a low dose and the dose increased gradually. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin and continue it throughout the treatment period. Rosuvastatin may be taken at any time of day, regardless of meals. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, and most patients are controlled at this dose. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response; the dose may be increased to a maximum of 20 mg once daily. 2. Older patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering rosuvastatin 20 mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but exposure increased in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration in patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Ethnicity: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5 mg. A dose of 40 mg is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of rosuvastatin 40 mg is contraindicated in some of these patients. In a drug interaction study of the active ingredients in this medicine, telmisartan/amlodipine 80/10 mg and rosuvastatin 20 mg, in the presence of telmisartan/amlodipine, rosuvastatin Cmax increased approximately 2.4-fold and AUC approximately 1.3-fold. Therefore, when administering this medicine, assess the potential risk associated with the increase in rosuvastatin Cmax and monitor the patient closely.

Precautions

This medication can cause serious harm to the fetus and newborn during pregnancy, so if pregnancy is confirmed, it should be immediately discontinued. Patients with hypersensitivity to any of the active ingredients or components of this medication, those with a history of certain angioedema, severe hepatic or renal impairment, or severe heart diseases should not take this medication. Elderly patients, those with hypotension, patients with mild hepatic dysfunction, and those at risk for muscle disorders should exercise special caution when taking this medication. This medication may cause musculoskeletal adverse reactions such as myalgia or muscle weakness, so if such symptoms occur during treatment, consult a doctor immediately. Since this medication may affect liver function, regular monitoring of liver enzyme levels before and during treatment is recommended. Additionally, this medication can affect serum potassium levels, posing a risk of hyperkalemia, so testing of serum electrolytes may also be necessary. Given the potential for drug interactions, patients should inform their physician or pharmacist of all medications they are taking. It is advisable to avoid the use of this medication during breastfeeding, and if it must be used, breastfeeding should be discontinued. Overdose may lead to symptoms such as hypotension, dizziness, and heart-related abnormal symptoms, which require immediate medical attention. This medication is not recommended for children or adolescents under 18, as safety and efficacy have not been established. Patients should be cautious when driving or operating machinery as dizziness or drowsiness may occur during treatment. Keep this medication out of reach of children and do not transfer it to another container.

Side effects

Viral upper respiratory tract infection, dyspnea, rectal bleeding, dyspepsia, atopic dermatitis, peripheral edema, peripheral edema, dizziness, orthostatic hypotension, low back pain, headache, hepatocellular carcinoma, cerebral infarction, congestive heart failure, musculoskeletal pain, neck pain, nasopharyngitis, upper abdominal discomfort, upper abdominal pain, positional vertigo, dysuria, rhinitis, discomfort in the oropharynx, pulmonary disease, unspecified intestinal disease, benign gastrointestinal neoplasm, hemorrhoids, skeletal pain, osteoporosis, sensory loss, movement disorder, atherosclerosis, frequent urination, tinnitus, hearing loss, bad breath, fatty liver, upper respiratory infection, low back pain, sinusitis, diarrhea, pharyngitis, influenza-like symptoms, dyspepsia, myalgia, urinary tract infection, abdominal pain, headache, dizziness, pain, fatigue, cough, hypertension, chest pain, nausea, palpitations, dependent edema, angina, rapid pulse, leg edema, abnormal ECG, insomnia, drowsiness, migraine, vertigo, sensory abnormalities, involuntary muscle contractions, erectile dysfunction, increased sweating, flushing, allergy, fever, leg pain, malaise, palpitations, vascular edema, vascular edema, polymorphic erythema, pruritus, rash, erythematous rash, papular rash, frequent urination, cystitis, thrombocytopenia, thrombocytopenia, leukopenia, purpura, thrombocytopenia, heart failure, irregular pulse, ectopic beats, skin depigmentation, pruritus, dry skin, hair loss, dermatitis, muscle weakness, single contraction, ataxia, hypertonia, migraine, chilly moist skin, apathy, amnesia, gastritis, increased appetite, watery stool, rhinitis, urinary disorders, polyuria, abnormal olfaction, taste disturbance, abnormal ocular accommodation, dry eye syndrome, gynecomastia, jaundice, liver enzyme elevation, leukopenia, confusion, exfoliative dermatitis, Stevens-Johnson syndrome, photosensitivity reaction, toxic epidermal necrolysis, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, cough, dyspnea, diarrhea, jaundice, hepatitis, transaminase elevation, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive decline, forgetfulness, amnestic disorder, memory disturbance, confusion, myasthenia gravis, ocular myasthenia, hypotension, tachycardia, bradycardia, dizziness, acute renal failure, excessive peripheral vasodilation, reflex tachycardia, systemic hypotension, shock state, shock, nausea, weakness, fatigue, facial edema, limb edema, vascular edema, hypersensitivity reaction, increased sweating, erythema, chest pain, atrial fibrillation, congestive heart failure, myocardial infarction, increased blood pressure, worsening hypertension, hypotension, hyperkalemia, hypoglycemia, syncope, dyspepsia, diarrhea, gout, increased uric acid, thrombocytopenia, acute renal failure, anemia, elevated CPK, anaphylactic reaction, tendon pain, rhabdomyolysis, muscle cramps, myalgia, increased CK, elevated ALT, elevated AST, weakness, arthralgia, fatigue, numbness, sensory abnormalities, chest discomfort, decreased appetite, abdominal distension, syncope, systemic pain, gout, erectile dysfunction

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a sealed container that protects from light and air. It is best to maintain the storage temperature between 1 to 30 degrees Celsius at room temperature.

Appearance and packaging

Appearance

Pink oval film-coated tablet

Package unit

30 tablets (10 tablets x 3) / PTP

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.